Goldman Sachs initiated coverage of NewAmsterdam Pharma (NAMS) with a Neutral rating and $27 price target The firm sees the stock as range-bound with results from the Phase 3 PREVAIL cardiovascular outcomes trial for the company’s lead candidate obicetrapib is not expected until late 2026. However, Goldman is “constructive” on obicetrapib’s LDL-C lowering and other lipid effects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma Updates Employment Agreement with Executive
- NewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald
- NewAmsterdam Pharma initiated with a Buy at Citi
- Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
- NewAmsterdam Pharma Schedules R&D Day for June 2025